CStone Pharmaceuticals, a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced that the GEMSTONE-302 registrational clinical study of sugemalimab for the first-line treatment of metastatic non-small cell lung cancer met the overall survival endpoint.
January 18, 2022
· 7 min read